Sunday 11 October 2026 Export all LLY data to Excel Powerpack

Eli Lilly and Company

LLY Healthcare Drug Manufacturers General

Eli Lilly and Company’s revenue for fiscal 2025 (year ended December 2025) was $65.2 billion, up 44.7% from fiscal 2024. In the quarter to June 2026, revenue grew 47.7%, EPS grew 26.2%, free cash flow grew 458.1% and total debt rose 37.6%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years, revenue growth for five.

1,179.27 9.67 +0.83%
Market cap
$1.10T
P/E
39.6×
Fwd P/E
33.1×
Dividend yield
0.57%
F-score
7/9
Altman Z
8.61
Beneish M
−1.91
Dividend safety
86/100
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

37.33 46.83 32.67 40.25
P/S ratio
11.52 14.79 11.39 13.44
P/FCF ratio
59.65 86.31 58.67 52.49
P/Operating CF
77.45 299.05 154.27 100.13
P/B ratio
28.69 36.34 26.37 31.59
EV/Sales
12.13 15.34 11.88 14.01
EV/EBITDA
29.38 35.32 25.58 31.24
EV/FCF
62.85 89.46 61.21 54.75
Current Ratio
1.55 1.58 1.50 1.35
Net Debt/EBITDA
3.95 3.93 3.62 4.83
Debt/Equity
1.71 1.60 1.26 1.62
Earnings Yield
2.68% 2.14% 3.06% 2.48%
Free Cash Flow Yield
1.68% 1.16% 1.70% 1.91%
Free Cash Flow per Share
7.52 0.76 3.36 8.69
Book value per Share
26.59 29.57 34.88 37.96
Free Cash Flow
6,748.10 677.90 3,007.00 7,757.00
EV/EBIT
31.85 38.00 27.23 33.19
Other line items

Show all line items

Columns are period end dates